Search clinical trials for: 14C-labeled ACT-541468

Total 100 results

Idorsia Pharmaceuticals Ltd.

Completed

A Single Ascending Dose Study of ACT-541468 in Healthy Male Subjects

Healthy Subjects

Netherlands
Idorsia Pharmaceuticals Ltd.

Completed

A Clinical Study to Investigate the Food Effect on the Pharmacokinetics of ACT-541468 in Healthy Male Subjects

Healthy

Czechia
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of ACT-541468 in Healthy Young Adults and Elderly Subjects

Healthy Subjects

Netherlands
Idorsia Pharmaceuticals Ltd.

Terminated

A Study in Healthy Subjects to Investigate the Safety and Tolerability of ACT- 541478 as Well as What ACT-541478 Does to the Body and the Way the Body Takes up, Distributes, and Gets Rid of ACT-541478

Healthy

Germany
Idorsia Pharmaceuticals Ltd.

Completed

Study of the Way the Body Takes up, Distributes, and Gets Rid of ACT-541468 in Subjects With Abnormal Kidney Function Compared to Healthy Subjects

Healthy | Renal Insufficiency

Germany
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Investigate the Effects of ACT-541468 on Nighttime Respiratory Function in Patients With Mild to Moderate Obstructive Sleep Apnea

Obstructive Sleep Apnea

Germany
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Investigate the Effects of Daridorexant on Nighttime Breathing in Patients With Shallow or Paused Breath During Sleep

Obstructive Sleep Apnea of Adult

Germany
Idorsia Pharmaceuticals Ltd.

Completed

Efficacy and Safety of ACT-541468 in Elderly Subjects With Insomnia Disorder

Insomnia Disorder

United States, Germany
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Evaluate the Effects of ACT-541468 on Respiration in Patients With Moderate Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

Germany
Idorsia Pharmaceuticals Ltd.

Completed

A Study of ACT-541468 in Healthy Japanese and Caucasian Subjects

Healthy Subjects

Netherlands
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Evaluate the Pharmacokinetics of ACT-541468 in Subjects With Mild, Moderate, and Severe Hepatic Impairment

Hepatic Impairment

Switzerland
Spectrum Pharmaceuticals, Inc

Terminated

A Mass Balance and Pharmacokinetics Study of 14C-Labeled Poziotinib in Cancer Patients Suitable for Treatment With Poziotinib

Solid Tumor

United States
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate the Effect of ASP1707 on the Bodies of Healthy Male Subjects After a Single Dose of Radioactive ASP1707

Pharmacokinetics of ASP1707

United Kingdom
Poxel SA

Completed

Pharmacokinetics and Metabolism of (14C)-Labelled PXL770

Healthy

United Kingdom
Astellas Pharma Inc

Completed

A Study to Assess the Systemic Disposition of ASP1585 After Administration of 14C-labeled Drug

Healthy | Pharmacokinetics of ASP1585

United States
M.D. Anderson Cancer Center
Theravance Biopharma

Completed

Study to Evaluate the Safety and Efficacy of Telavancin in the Treatment of Gram Positive Bloodstream Infections in Cancer Patients

Bacteremia | Infection

United States
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Examine the Safety, Tolerability, and Pharmacokinetics of Single- and Multiple-ascending Doses of ACT-1014-6470 in Healthy Subjects

Healthy

Netherlands
Idorsia Pharmaceuticals Ltd.

Completed

Efficacy and Safety of ACT-541468 in Adult Subjects With Insomnia Disorder

Insomnia Disorder

United States, Germany, Spain, Hungary, Israel, Sweden
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Study to Investigate the Absorption, Metabolism and Excretion of [14C] Anlotinib in Patients With Advanced Cancer Patients

Advanced Solid Tumors

China
Astellas Pharma Global Development, Inc.

Completed

Study to Investigate the Absorption, Metabolism and Excretion of [14C] ASP2215 in Patients With Advanced Solid Tumors

Advanced Solid Tumors | Pharmacokinetics of 14C-labeled Gilteritinib

United States
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Evaluate ACT-132577 in Healthy Male Subjects

Healthy Subjects

Netherlands
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Investigate the Drug-drug Interactions Between ACT-541468 and Ethanol in Healthy Subjects

Healthy

Netherlands
Genfit
SGS Life Sciences, a division of SGS Belgium NV

Completed

Mass Balance Study of 14C-labelled GFT505 in Healthy Volunteers

Healthy

Belgium
KU Leuven

Completed

Determination of the Bioavailability of Short Chain Fatty Acids in Healthy Humans

Short Chain Fatty Acids Bioavailability

Belgium
Pfizer

Completed

Single Dose Study With Unlabeled Dose and 14C-labeled Microdose of PF-06700841 in Healthy Male Subjects

Healthy Male Subjects

Netherlands
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Examine the Safety, Tolerability, and Pharmacokinetics of Single- and Multiple-ascending Doses of ACT-777991 in Healthy Subjects

Healthy

Netherlands
Merck KGaA, Darmstadt, Germany
Threshold Pharmaceuticals

Completed

A Phase 1 TH-302 Mass Balance Trial

Solid Tumor

Germany
Astellas Pharma Global Development, Inc.

Completed

A Study to Learn How [14C]ASP0367 is Processed by the Body in Healthy Men

Healthy Volunteers

United States
Abbott

Terminated

A Pharmacokinetic Study to Access How the Body Absorbs and Removes Linifanib in Male Patients With Advanced Solid Tumors.

Advanced Solid Tumors

United States
Alexion Pharmaceuticals
Achillion, a wholly owned subsidiary of Alexion

Completed

Study of Radiolabeled Danicopan in Healthy Male Participants

Healthy

New Zealand
Alexion Pharmaceuticals

Completed

Study of Radiolabeled ALXN2050 in Healthy Adult Males

Healthy

United States
Iowa State University

Enrolling by invitation

A Randomized Controlled Trial of ACT-P Versus T4C for Community Reentry

Violence | Criminal Behavior

United States
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)

Recruiting

Investigating Targetable Metabolic Pathways Sustaining Pancreatic Cancer

Pancreatic Ductal Adenocarcinoma

United States
Astellas Pharma Global Development, Inc.
Basilea Pharmaceutica International Ltd

Completed

Study to Evaluate the Pharmacokinetics of 14C-labeled Isavuconazole Following a Single Oral Dose of 14C-labeled Prodrug Isavuconazonium Sulfate (BAL8557) in Healthy Male Subjects

Healthy Subjects | Pharmacokinetics of 14C-labeled Isavuconazole

United States
University of Alabama at Birmingham

Withdrawn

Neuroinflammation and Age-associated Brain Pathology: Two Potential Mechanisms of Cognitive Impairment in Ovarian Cancer

Ovarian Cancer

United States
Astellas Pharma Global Development, Inc.
Basilea Pharmaceutica International Ltd

Completed

A Study to Evaluate the Pharmacokinetics of BAL8728 After a Single Dose of Pyridinylmethyl-14C-Labeled Isavuconazonium Sulfate in Healthy Male Subjects

Healthy Subjects | Pharmacokinetics of 14C-labeled Isavuconazonium Sulfate

United States
Merck Sharp & Dohme LLC
Pfizer

Completed

A Phase 1 Study of Ertugliflozin in Healthy Male Participants (MK-8835-020)

Type 2 Diabetes Mellitus
Medicines for Malaria Venture
Shin Poong Pharmaceuticals

Completed

Human Mass Balance Study of Pyronaridine

Malaria

Switzerland
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Dysregulation of Glutamine Activity in the Pathogenesis of Multiple Myeloma

Monoclonal Gammopathy of Undetermined Significance | Plasma Cell Myeloma

United States
Idorsia Pharmaceuticals Ltd.

Completed

A Study in Healthy Male Subjects to Investigate Whether Administration of ACT-541468 Can Affect the Fate in the Body (Amount and Time of Presence in the Blood) of Rosuvastatin

Healthy Subjects

Czechia
Acerta Pharma BV

Completed

A Study to Evaluate the Effect of [14C]Acp-196 (Acalabrutinib) in Healthy Adult Participants

Healthy Volunteers

United States
Idorsia Pharmaceuticals Ltd.

Completed

A Clinical Study to Assess Next-day Driving Performance Following Administration of ACT-541468 in Middle-aged and Elderly Subjects

Healthy

Netherlands
Sirtris, a GSK Company
GlaxoSmithKline

Completed

A Clinical Study to Evaluate the Pharmacokinetics and the Absolute Bioavailability of SRT2104 Given as a 250mg Oral Suspension and Intravenous Microdose of 100 µg Carbon-14 Radio-labeled SRT2104 in Healthy Male Subjects

Diabetes Mellitus, Type 2

United Kingdom
AbbVie
Genentech, Inc.

Withdrawn

A Pharmacokinetic Study to Access How the Body Absorbs and Removes ABT-199 in Adults With Non-Hodgkin's Lymphoma

Relapsed/Refractory Non-Hodgkin's Lymphoma
Hangzhou ACEA Pharmaceutical Research Co., Ltd.

Completed

Study to Investigate the Absorption, Metabolism and Excretion of [14C] AC0010 in Patients With Advanced NSCLC

Carcinoma, Non-Small-Cell Lung

China
Idorsia Pharmaceuticals Ltd.

Completed

Pharmacokinetic Interaction Between Diltiazem and ACT-541468 in Healthy Subjects

Healthy Subjects

Germany
Hoffmann-La Roche

Completed

Bioavailability Study of Vemurafenib in Participants With BRAF^V600 Mutation-Positive Malignancies

Malignant Melanoma, Cancer

Hungary
University of California, Davis
National Institutes of Health (NIH); Lawrence Livermore National Laboratory

Terminated

Clinical Study of Microdosing Carboplatin in Lung or Bladder Cancer

Carcinoma, Non-Small-Cell Lung | Urinary Bladder Neoplasms

United States
MEI Pharma, Inc.
SCRI Development Innovations, LLC

Completed

Phase I Dose Escalation Study of the Safety and Pharmacokinetics of ME-143 Single Agent for Refractory Solid Tumors

Solid Tumors

United States
Chang Gung Memorial Hospital

Not yet recruiting

13C Pyruvate DNP MR Spectroscopy for Lymphoma Treatment Response Assessment

Patient Outcome Assessment

3

Subscribe